Pegylated Liposomal Doxorubicin: Antitumor Activity in Epithelial Ovarian Cancer or Cancers of Peritoneal Origin

Franco M. Muggia; Tamar Safra; Susan Groshen; Susan Jeffers; R. N. Lynda Roman; Matthew Tan; Laila Muderspach; Alexander Burnett; Silvia Formenti; C. Paul Morrow; Michael Amantea

Pegylated Liposomal Doxorubicin: Antitumor Activity in Epithelial Ovarian Cancer or Cancers of Peritoneal Origin

Franco M. Muggia^*
, Tamar Safra
, Susan Groshen
, Susan Jeffers
, R. N. Lynda Roman
, Matthew Tan
, Laila Muderspach
, Alexander Burnett
, Silvia Formenti
, C. Paul Morrow
, Michael Amantea

^*Corresponding author for this work

Oncology

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

After pegylated liposomal doxorubicin (PEG-LD) (Doxil) was shown to be active in ovarian tumors, several trials were developed at the University of Southern California to determine its safety and efficacy in a variety of gynecologic and peritoneal malignancies. Completed phase I and phase II trials have found PEG-LD to be safe and effective in the treatment of platinum- and paclitaxel-refractory epithelial ovarian carcinoma, A new phase II trial is currently underway in similarly refractory patients with ovarian and other related cancers and various degrees of pretreatment. In addition, the efficacy of PEG-LD is being explored in combination with paclitaxel (Taxol), with cisplatin, and with hyperthermia.

Original language	English
Pages (from-to)	38-44
Number of pages	7
Journal	Oncology
Volume	11
Issue number	10 SUPPL. 12
State	Published - 1997

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{9b1d362d3a3e4dbdb7e883bd7c894664,

title = "Pegylated Liposomal Doxorubicin: Antitumor Activity in Epithelial Ovarian Cancer or Cancers of Peritoneal Origin",

abstract = "After pegylated liposomal doxorubicin (PEG-LD) (Doxil) was shown to be active in ovarian tumors, several trials were developed at the University of Southern California to determine its safety and efficacy in a variety of gynecologic and peritoneal malignancies. Completed phase I and phase II trials have found PEG-LD to be safe and effective in the treatment of platinum- and paclitaxel-refractory epithelial ovarian carcinoma, A new phase II trial is currently underway in similarly refractory patients with ovarian and other related cancers and various degrees of pretreatment. In addition, the efficacy of PEG-LD is being explored in combination with paclitaxel (Taxol), with cisplatin, and with hyperthermia.",

author = "Muggia, \{Franco M.\} and Tamar Safra and Susan Groshen and Susan Jeffers and \{Lynda Roman\}, \{R. N.\} and Matthew Tan and Laila Muderspach and Alexander Burnett and Silvia Formenti and \{Paul Morrow\}, C. and Michael Amantea",

year = "1997",

language = "אנגלית",

volume = "11",

pages = "38--44",

journal = "Oncology",

issn = "0890-9091",

publisher = "UBM Medica Healthcare Publications",

number = "10 SUPPL. 12",

}

TY - JOUR

T1 - Pegylated Liposomal Doxorubicin

T2 - Antitumor Activity in Epithelial Ovarian Cancer or Cancers of Peritoneal Origin

AU - Muggia, Franco M.

AU - Safra, Tamar

AU - Groshen, Susan

AU - Jeffers, Susan

AU - Lynda Roman, R. N.

AU - Tan, Matthew

AU - Muderspach, Laila

AU - Burnett, Alexander

AU - Formenti, Silvia

AU - Paul Morrow, C.

AU - Amantea, Michael

PY - 1997

Y1 - 1997

N2 - After pegylated liposomal doxorubicin (PEG-LD) (Doxil) was shown to be active in ovarian tumors, several trials were developed at the University of Southern California to determine its safety and efficacy in a variety of gynecologic and peritoneal malignancies. Completed phase I and phase II trials have found PEG-LD to be safe and effective in the treatment of platinum- and paclitaxel-refractory epithelial ovarian carcinoma, A new phase II trial is currently underway in similarly refractory patients with ovarian and other related cancers and various degrees of pretreatment. In addition, the efficacy of PEG-LD is being explored in combination with paclitaxel (Taxol), with cisplatin, and with hyperthermia.

AB - After pegylated liposomal doxorubicin (PEG-LD) (Doxil) was shown to be active in ovarian tumors, several trials were developed at the University of Southern California to determine its safety and efficacy in a variety of gynecologic and peritoneal malignancies. Completed phase I and phase II trials have found PEG-LD to be safe and effective in the treatment of platinum- and paclitaxel-refractory epithelial ovarian carcinoma, A new phase II trial is currently underway in similarly refractory patients with ovarian and other related cancers and various degrees of pretreatment. In addition, the efficacy of PEG-LD is being explored in combination with paclitaxel (Taxol), with cisplatin, and with hyperthermia.

UR - https://www.scopus.com/pages/publications/0030828846

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:0030828846

SN - 0890-9091

VL - 11

SP - 38

EP - 44

JO - Oncology

JF - Oncology

IS - 10 SUPPL. 12

ER -

Pegylated Liposomal Doxorubicin: Antitumor Activity in Epithelial Ovarian Cancer or Cancers of Peritoneal Origin

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this